CHAPEL HILL, NORTH CAROLINA--(Marketwire - Feb. 22, 2011) - Adherex Technologies Inc. (TSX:AHX)(PINK SHEETS:ADHXF) ("Adherex") announced today that the record date for its previously announced rights offering has been changed from 5:00 pm, New York City time on February 24, 2011 to March 2, 2011, at which time the subscription period will commence. No other changes have been made to the previously announced rights offering, the terms of which are described in a prospectus contained in a registration statement filed with the SEC, as amended, and in a short form prospectus, as amended, filed with the securities regulatory authorities in Canada. Shareholders wishing to exercise their rights must return their completed certificate along with the applicable funds as directed, on or before the expiration date, which is scheduled to be 5:00 pm New York City time, on March 29, 2011.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor sell there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
This press release contains forward-looking statements within the meaning of the United States Federal and Canadian provincial securities laws. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2009. Adherex Technologies, Inc. disclaims any obligation to update these forward-looking statements except as required by law.
For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.